| 2024 |
Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis |
Articolo in rivista |
Vai |
| 2024 |
Citrus wastewater as a source of value‐added products: Quali‐quantitative analysis and in vitro screening on breast cancer cell lines |
Articolo in rivista |
Vai |
| 2024 |
Chaperoning system: Intriguing target to modulate the expression of CFTR in cystic fibrosis |
Articolo in rivista |
Vai |
| 2023 |
Exploring the anticancer activity and the mechanism of action of pyrrolomycins F obtained by microwave-assisted total synthesis |
Articolo in rivista |
Vai |
| 2023 |
Insight into non-nucleoside triazole-based systems as viral polymerases inhibitors |
Review essay (rassegna critica) |
Vai |
| 2023 |
HSV-1 Glycoprotein D and Its Surface Receptors: Evaluation of Protein–Protein Interaction and Targeting by Triazole-Based Compounds through In Silico Approaches |
Articolo in rivista |
Vai |
| 2023 |
Advances in developing noncovalent small molecules targeting Keap1 |
Review essay (rassegna critica) |
Vai |
| 2023 |
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib |
Articolo in rivista |
Vai |
| 2023 |
Editorial: Emerging heterocycles as bioactive compounds |
Nota o commento |
Vai |
| 2023 |
Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel |
Articolo in rivista |
Vai |
| 2023 |
Identification of pyrrolo[3′,4’:3,4]cyclohepta[1,2-d][1,2]oxazoles as promising new candidates for the treatment of lymphomas |
Articolo in rivista |
Vai |
| 2022 |
Synthesis of 2H-Imidazo[2′,1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations |
Articolo in rivista |
Vai |
| 2022 |
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences |
Review essay (rassegna critica) |
Vai |
| 2022 |
New tricyclic systems as photosensitizers towards triple negative breast cancer cells |
Articolo in rivista |
Vai |
| 2022 |
Novel insights on [1,2]oxazolo[5,4‐e]isoindoles on multidrug resistant acute myeloid leukemia cell line |
Articolo in rivista |
Vai |
| 2022 |
Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas |
Articolo in rivista |
Vai |
| 2022 |
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma |
Articolo in rivista |
Vai |
| 2022 |
Insight on pyrimido[5,4-g]indolizine and pyrimido[4,5-c]pyrrolo[1,2-a]azepine systems as promising photosensitizers on malignant cells |
Articolo in rivista |
Vai |
| 2022 |
Transcriptome and computational analysis assess the anti-tubulin activity of [1,2]oxazole derivatives in lymphoma |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2022 |
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma |
Articolo in rivista |
Vai |
| 2022 |
GPCR Inhibition in Treating Lymphoma |
Review essay (rassegna critica) |
Vai |
| 2021 |
Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity |
Review essay (rassegna critica) |
Vai |
| 2021 |
THE KEY ROLE OF THE CLINICAL PHARMACIST IN THE MANAGEMENT OF ANTICANCER THERAPIES: A PILOT STUDY IN THE TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER |
Articolo in rivista |
Vai |
| 2021 |
Insight on [1,3]thiazolo[4,5-e]isoindoles as tubulin polymerization inhibitors |
Articolo in rivista |
Vai |
| 2021 |
Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein |
Articolo in rivista |
Vai |
| 2020 |
Evaluation of [1,2]oxazolo[5,4-e]isoindoles in lymphoma cells |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2020 |
Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2020 |
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes |
Articolo in rivista |
Vai |
| 2020 |
An overview on anti-tubulin agents for the treatment of lymphoma patients |
Articolo in rivista |
Vai |
| 2020 |
Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types |
Articolo in rivista |
Vai |
| 2020 |
Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2020 |
Current development of CFTR potentiators in the last decade |
Articolo in rivista |
Vai |
